Yes, semaglutide can cause diarrhea, and it is one of the side effects people notice most. In the trials behind Wegovy, about 3 in 10 adults on the 2.4 mg weekly dose reported it at some point, compared with about 1 in 6 on placebo. At the lower doses used for type 2 diabetes it was closer to 1 in 11. Semaglutide diarrhea tends to show up while the dose is still climbing, and a typical episode in those trials lasted about three days. Diarrhea that doesn't settle, or that comes with signs of dehydration, is the kind to call the prescriber about rather than wait out.
Constipation, the other half of the bowel story, runs on a much slower clock and has its own guide.
Does semaglutide cause diarrhea?
Yes. Watch the placebo column: people get diarrhea anyway, from food, stomach bugs and ordinary life, so the drug's real share is the gap between the two numbers.
| Product and dose (who was studied) | On semaglutide | On placebo |
|---|---|---|
| Wegovy 2.4 mg weekly (three weight-loss trials) | 30% | 16% |
| STEP 1 alone (1,961 adults without diabetes) | 31.5% | 15.9% |
| Ozempic 0.5 mg weekly (type 2 diabetes) | 8.5% | 1.9% |
| Ozempic 1 mg weekly (type 2 diabetes) | 8.8% | 1.9% |
| Rybelsus tablets 7 mg / 14 mg daily (type 2 diabetes) | 9% / 10% | 4% |
Sources: the Wegovy prescribing information (Revised: 6/2026), the Ozempic prescribing information (Revised: 5/2026), the Rybelsus label (Revised: 1/2026) and the STEP 1 trial in the New England Journal of Medicine, 2021.
Rates run higher at the weight-loss dose, though the people studied differed too. The STEP 1 authors called nausea and diarrhea "typically transient and mild-to-moderate in severity."
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The numbers above come from trials of the brand-name products, which remain the best guide to what the molecule itself does.
How long semaglutide diarrhea lasts
Usually days, not weeks, per episode. A 2022 analysis pooling the STEP 1, 2 and 3 trials, with 2,117 people on semaglutide 2.4 mg and 1,262 on placebo, found the median diarrhea episode lasted 3 days, about the same as on placebo (Wharton et al., Diabetes, Obesity and Metabolism, 2022). Median means half the episodes were shorter and half longer.
The timing follows the dose. In those trials the dose rose every four weeks, reaching 2.4 mg at week 16. Diarrhea was most widespread around week 20, just after the last step up, and became less common after that. It never quite fell to placebo levels over the 68 weeks, so a later episode isn't unheard of, and it tends to flare around dose increases. For comparison, the median nausea episode lasted 8 days and constipation 47.
Diarrhea is also not a sign the medicine is working harder. In the pooled data, weight loss was similar with or without stomach side effects, and they accounted for less than one percentage point of the extra weight loss over placebo.
Why semaglutide can cause diarrhea
Nobody has fully pinned it down. Semaglutide copies GLP-1, a gut hormone released after meals, whose receptors sit all along the digestive tract. Its best-known effect, slowing how fast the stomach empties, explains fullness and nausea better than diarrhea. The Wharton team wrote that changes in how quickly things move through the lower gut may play a part, "although evidence is lacking."
A Spanish expert consensus on GLP-1 side effects noted that long-acting drugs in the class, the group semaglutide belongs to, have been linked with less nausea but more diarrhea, possibly because they act on intestinal receptors for longer (Gorgojo-Martínez et al., Journal of Clinical Medicine, 2022). It also flags an everyday contributor: GLP-1 drugs may worsen diarrhea in people taking metformin, a common diabetes medicine.
As of September 22, 2026, the day this article was written, two recent papers point the other way. A July 2026 case series described 30 people with severe, long-standing diarrhea, from causes such as bile acid diarrhea and short bowel syndrome, whose doctors tried semaglutide; their median daily bowel movements fell from 8 to 2 (Nielsen et al., Scandinavian Journal of Gastroenterology, 2026). An August 2026 records study of people with irritable bowel syndrome found slightly less recorded chronic diarrhea in those who started a GLP-1 drug than in similar patients who didn't, 8.9% against 10.6% (Khan et al., Digestive Diseases and Sciences, 2026). Neither was a randomized trial, but both show the drug's gut effects run in more than one direction, which is why a prescriber wants to hear about any existing bowel condition.
What a prescriber may discuss for diarrhea
Most of the conversation is practical. The Spanish consensus lists measures clinicians commonly go over:
- Generous fluids, sipped through the day.
- Easing off, for a while, dairy, coffee, alcohol, very high-fibre foods, and sugar-free sweets or gum made with sorbitol or xylitol.
- Plainer, lower-fat food in smaller portions, such as rice, broth and very ripe peeled fruit.
The Wegovy Medication Guide puts the fluid point plainly: "It is important for you to drink fluids to help reduce your chance of dehydration." If diarrhea persists anyway, the consensus says a clinician could consider an anti-diarrheal medicine or a probiotic, or revisit a metformin dose. Those depend on other medicines, kidney function and the actual cause, so they're the prescriber's call.
So is the dose plan. The Wegovy label says a prescriber can consider delaying the next increase by 4 weeks when a dose isn't tolerated, and that after 2 or more missed weekly doses in a row, escalation restarts at a lower dose "to reduce the risk of gastrointestinal adverse reactions."
As of September 22, 2026, the day this article was written, a July 2026 case report illustrated that rule: a woman who restarted semaglutide 2.4 mg at full dose after a five-week break developed severe nausea, vomiting and diarrhea the next day and spent four days in hospital (Valizada and Zilbermint, Cureus, 2026). One case can't show how often that happens, but it's why a gap in treatment is worth raising with the prescriber before the next dose.
When semaglutide diarrhea needs a call
The Wegovy and Ozempic labels both carry a warning titled "Acute Kidney Injury Due to Volume Depletion," meaning kidney injury after losing more fluid than is taken in. It rests on postmarketing reports (cases sent in after a drug is on the market, which can't show how often something happens), "in some cases requiring hemodialysis," mostly in people dehydrated by nausea, vomiting or diarrhea. A second warning covers severe stomach and bowel reactions: 4.1% of people on Wegovy injection in the weight-loss trials, against 0.9% on placebo.
In practice, diarrhea that lasts more than a few days, outpaces drinking, or comes with vomiting deserves a same-day call, as do very little or very dark urine, strong thirst, dizziness on standing or unusual weakness. Blood or black stool, fever, severe belly pain, fainting, confusion or being unable to keep fluids down call for urgent care; those aren't typical dose-adjustment symptoms.
If it doesn't settle: stay, slow down or switch
When diarrhea keeps disrupting daily life, the options include more time at the current dose, a slower climb, a lower dose or a different medicine. Switching isn't an automatic fix. Tirzepatide causes diarrhea too; in its main obesity trial, SURMOUNT-1, roughly 1 in 5 participants reported it across the three doses, against fewer than 1 in 10 on placebo (ClinicalTrials.gov results record). The tirzepatide diarrhea guide covers its pattern, and the semaglutide side-effects guide covers the rest of this medicine's profile.
Whether to stay, slow down or switch, and whether a compounded formulation is the right route at all, is a decision between the patient and the prescribing provider. At Promise, a licensed provider reviews every request, and not everyone qualifies. If semaglutide is prescribed, persistent diarrhea and any dose change go through that same provider.